Clinical trial
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type…
NCT00444678 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00444678 |
|---|---|
| Title | Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer |
| Official title | A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With KRAS Wild Type Metastatic Colorectal Cancer |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | Eli Lilly and Company Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Cetuximab, Oxaliplatin, Capecitabine |
| Enrollment | 36 |
| Start date | Jun 1, 2004 |
| Primary completion | Aug 1, 2012 |
| Completion | Jun 1, 2015 |
| First posted | Mar 8, 2007 |
| Last update posted | Apr 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: